PedAM
Pediatric Disease Annotations & Medicines
| Disease | allergic conjunctivitis |
| Symptom | C0033774|itching |
| Sentences | 16 |
| PubMedID- 20406593 | Formulation, pataday (alcon laboratories, inc.), to treat itching associated with allergic conjunctivitis. |
| PubMedID- 21250860 | The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. |
| PubMedID- 26185412 | It has a ph ~7 and an osmolality ~290 mosm/kg.59 alcaftadine is dosed once per day in each eye for the prevention of itching associated with allergic conjunctivitis in individuals beginning at 2 years of age. |
| PubMedID- 23152650 | Bepotastine besilate 1.5% was approved by the us food and drug administration in 2009 for the treatment of ocular itching associated with allergic conjunctivitis, with twice a day dosing in patients 2 years of age and older.9 bepotastine besilate 1.5% has undergone three randomized, placebo-controlled us clinical studies, two conjunctival allergen challenge studies, and a six-week safety study with twice-daily dosing. |
| PubMedID- 21386912 | Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis. |
| PubMedID- 22811343 | Conclusions: alcaftadine is a safe and effective option for the prevention of ocular itching associated with allergic conjunctivitis, is dosed once daily, and is competitively priced among prescription medications for allergic conjunctivitis. |
| PubMedID- 21179226 | Ketorolac is a nonsteroidal anti-inflammatory drug with analgesic and anti- inflammatory properties.1 currently available ophthalmic formulations of ketorolac include a 0.5% solution (acular®; allergan inc., irvine, ca), indicated for treatments of inflammation following cataract extraction and ocular itching due to seasonal allergic conjunctivitis, and a 0.4% solution, (acular ls®; allergan inc.), indicated for treatment of pain and burning/stinging after corneal refractive surgery.2,3 both of these ketorolac formulations are indicated for instillation 4 times daily. |
| PubMedID- 24082771 | The clinical presentation of external ophthalmomyasis is similar to viral or allergic conjunctivitis, with tearing, itching, hyperemia, and foreign-body sensation. |
| PubMedID- 23776804 | Patients with marked bilateral ocular itching and history of seasonal allergic conjunctivitis confirmed by a positive skin test to appropriate pollen were included in the study. |
| PubMedID- 22348913 | Food and drug administration for prevention of itching associated with allergic conjunctivitis in patients over 2 years of age. |
| PubMedID- 24109191 | A more concentrated formulation of 0.2% was later approved for once-daily treatment of ocular itching associated with allergic conjunctivitis.8 alcaftadine 0.25% ophthalmic solution was approved by the fda in 2011 as a once-daily therapeutic treatment for the prevention of itching associated with allergic conjunctivitis.9 these are the only topical antihistamines with this long duration of action currently available. |
| PubMedID- 26392751 | The primary objective was to demonstrate the superiority of olopatadine 0.77% compared with its vehicle for the treatment of ocular itching associated with allergic conjunctivitis using the cac immediately after dosing for onset of action and 16 hours after dosing to determine the duration of action. |
| PubMedID- 25260889 | Introduction: the efficacy and safety of the once-daily topical ophthalmic solutions, alcaftadine 0.25% and olopatadine 0.2%, in preventing ocular itching associated with allergic conjunctivitis were evaluated. |
| PubMedID- 25873897 | Of potential interest is the drug alcaftadine that is a topical ophthalmic solution indicated for the prevention of itching associated with allergic conjunctivitis. |
| PubMedID- 21339800 | This effectiveness was demonstrated at 15 minutes and 16 hours after instillation, indicating that alcaftadine 0.25% has a rapid onset of action and a substantial duration of action, making it a candidate for once-daily dosing for the prevention of itching due to allergic conjunctivitis. |
| PubMedID- 22991696 | Bbos 1.5% is safe and effective in the treatment of ocular itching associated with allergic conjunctivitis within 3 minutes of a cac and with a sustained duration of action of at least 8 hours. |
Page: 1